Friday, April 20 , 2018, 11:59 am | Fair 62º

 
 
 
 

New Gift Boosts UCSB Biologist’s Work Toward Therapy for Polycystic Kidney Disease

With no cure, no approved treatment and no known means of slowing its progression, polycystic kidney disease is a biomedical cold case that affects more than 600,000 people in the U.S. alone — and some 12 million worldwide.

Thomas Weimbs
Thomas Weimbs

Hoping to crack that case with science, UC Santa Barbara biologist Thomas Weimbs is working to develop a new therapeutic approach by targeting the mechanism that causes the cysts to grow. A new gift to his lab is providing a big boost to that effort.

After a competitive selection process, the Lillian Goldman Charitable Trust of New York has awarded $600,000 to Weimbs to support his team’s continued work on autosomal-dominant polycystic kidney disease (ADPKD or PKD). Weimbs is one of the world’s top experts in the disease, a potentially fatal genetic condition that leads to renal failure and causes major cardiovascular complications.

“We are thrilled and grateful to have received funding from the Lillian Goldman Charitable Trust, which will greatly help to accelerate the progress of our research,” said Weimbs, a professor of molecular, cellular and developmental biology. “My lab is very focused on understanding the mechanisms that are most critical for the development of the thousands of cysts that eventually destroy both kidneys in PKD patients. We are driven by the motivation to develop a feasible therapy to at least slow disease progression and are working on several highly promising approaches in parallel. Philanthropic, targeted funding such as this can make a huge difference in speeding up the progress of research.”

Considered the most common life-threatening, monogenic inherited disease, PKD is a leading cause of kidney failure. With no viable treatment available, most patients eventually require a renal transplant or lifelong dialysis for survival. Research in Weimbs’ lab is aimed at understanding the molecular mechanisms that lead to renal cyst growth and disease progression — and at identifying and testing new strategies for therapy.

“This disease is slowly progressive, over decades, essentially, the kidneys grow bigger and bigger and become more cystic, and destroy the normal kidney tissue,” Weimbs said. “Usually when patients are in their fifties or so, on average, the tissue has been so destroyed that the kidneys stop functioning.”

More common than cystic fibrosis, muscular dystrophy, Down syndrome and sickle cell anemia combined, PKD affects one in 500 people worldwide. As it progresses, cysts grow and multiply such that a kidney can expand from the size of a human fist, which is normal, to be as large, or larger than, a football, and weigh nearly 40 pounds each.

Parents with the dominant form of the disease have a 50 percent chance of passing it on to each of their children.

Over the years there have been several clinical trials to test the efficacy of various drugs for treatment of PKD, Weimbs said, but most showed little, if any, benefit.

“Patients have high hopes that there may be a successful drug treatment out there, and I think they are correct but this has proven to be a hard nut to crack,” said Weimbs, who has been working on PKD for more than a dozen years. “It’s a genetic disease and the same gene mutation passes from parent to child. But strangely, the rate of progression is widely variable. While the parent may progress to end-stage renal failure at, say, 60, their child might have a faster progression and reach end stage 10 or 20 years earlier, or the other way around. It’s inconsistent.

“It has been speculated there could be other genetic factors at play, or even environmental factors,” Weimbs added. “We are exploring those possibilities and are particularly excited about identifying an environmental factor because this would potentially allow much easier intervention.”

— Shelly Leachman represents the UCSB Office of Public Affairs and Communications.

  • Ask
  • Vote
  • Investigate
  • Answer

Noozhawk Asks: What’s Your Question?

Welcome to Noozhawk Asks, a new feature in which you ask the questions, you help decide what Noozhawk investigates, and you work with us to find the answers.

Here’s how it works: You share your questions with us in the nearby box. In some cases, we may work with you to find the answers. In others, we may ask you to vote on your top choices to help us narrow the scope. And we’ll be regularly asking you for your feedback on a specific issue or topic.

We also expect to work together with the reader who asked the winning questions to find the answer together. Noozhawk’s objective is to come at questions from a place of curiosity and openness, and we believe a transparent collaboration is the key to achieve it.

The results of our investigation will be published here in this Noozhawk Asks section. Once or twice a month, we plan to do a review of what was asked and answered.

Thanks for asking!

Click Here to Get Started >

Support Noozhawk Today

You are an important ally in our mission to deliver clear, objective, high-quality professional news reporting for Santa Barbara, Goleta and the rest of Santa Barbara County. Join the Hawks Club today to help keep Noozhawk soaring.

We offer four membership levels: $5 a month, $10 a month, $25 a month or $1 a week. Payments can be made through PayPal below, or click here for information on recurring credit-card payments.

Thank you for your vital support.


Maestro, Mastercard, Visa, American Express, Discover, Debit

Reader Comments

Noozhawk is no longer accepting reader comments on our articles. Click here for the announcement. Readers are instead invited to submit letters to the editor by emailing them to [email protected]. Please provide your full name and community, as well as contact information for verification purposes only.

Daily Noozhawk

Subscribe to Noozhawk's A.M. Report, our free e-Bulletin sent out every day at 4:15 a.m. with Noozhawk's top stories, hand-picked by the editors.

Sign Up Now >